Full field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 ePoster … testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 AAO 2020 poster by Allen Ho et al. … November 13, 2020
ARVO (2021) Russell SR et al., Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) Presentation … in the second treated eye in a Ph1b/2 extension trial in Leber Congenital Amaurosis type 10 (LCA10) ARVO 2021 presentation by Stephen … May 06, 2021
Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene ePoster … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … November 13, 2020
Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 gene Presentation … (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber congenital amaurosis 10 (LCA10) due to p.Cys998X mutation in the CEP290 … June 17, 2020
Expert Perspectives Series – LCA10 and sepofarsen Webcast … – LCA10 and sepofarsen ProQR Expert Perspectives Series on Leber congenital amaurosis 10 and sepofarsen with Aniz Girach and Dr. Ian M. … July 20, 2020
ProQR Top-line results Phase 1/2 trial of sepofarsen in LCA10 patients Webcast ProQR presents Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients. October 10, 2019
ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 Press release … Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, Netherlands & CAMBRIDGE, Mass., April … April 13, 2021
“Top-notch science that leads to a treatment” Story … of her department, aimed at developing a novel drug for Leber congenital amaurosis 10 (LCA10) patients, has progressed steadily. The … March 31, 2017
Phase 2/3 Illuminate trial results of sepofarsen in CEP290-mediated LCA10 News update … news update: ProQR Update August 2022 . What is LCA10? Leber congenital amaurosis (LCA) is the most common genetic cause of childhood … February 11, 2022
Conference call top-line results Phase 2/3 Illuminate trial Webcast ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10. February 11, 2022
